Impacts of SNPs on adverse events and trough concentration of imatinib in patients with gastrointestinal stromal tumors

Author:

Maekawa KeikoORCID,Yamamura Masahiro,Matsuki Atsushi,Ishikawa Takashi,Hirai Toshihiro,Yamaguchi Yoshiyuki,Saito Yoshiro,Kanda Tatsuo

Funder

Japan Society for the Promotion of Science

Government of Japan Ministry of Health Labour and Welfare

Hoansha Foundation

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology

Reference38 articles.

1. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia;Cohen;Clin Cancer Res,2002

2. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors;Dagher;Clin Cancer Res,2002

3. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors;Demetri;N Engl J Med,2002

4. Management of gastrointestinal stromal tumour: current practices and visions for the future;Blay;Oncology,2015

5. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202);Nishida;Int J Clin Oncol,2008

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3